Cancer

Titlesort ascending Average Rating
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofe 50.00%
N-acetylcysteine inhibits proliferation, adhesion, migration and invasion of human bladder cancer cells. 80.00%
Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. 70.00%
Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. 80.00%
Inhibition of MIF Leads to Cell Cycle Arrest and Apoptosis in Pancreatic Cancer Cells. 40.00%
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and 50.00%
How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology. 80.00%
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. 80.00%
Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer. 40.00%
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patient 80.00%
Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells. 80.00%
Case report of a pituitary macroadenoma treated with artemether. 50.00%
Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo 60.00%
Anti-angiogenic therapies for metastatic colorectal cancer. 60.00%

Pages